Literature DB >> 23515947

Utility of one-step nucleic acid amplification (OSNA) assay in detecting breast cancer metastases of sentinel lymph nodes in a Chinese population.

Dali Li1, Xiaoli Xu, Jiajian Chen, Jiaying Chen, Benlong Yang, Wentao Yang, Weiping Xu, Jiong Wu, Daren Shi.   

Abstract

BACKGROUND: The one-step nucleic acid amplification (OSNA) assay is an innovative method for the diagnosis of sentinel lymph node (SLN) metastases in breast cancer patients. The aim of the present study was to clinically validate the OSNA assay and compare its results with postoperative serial sectioning in a Chinese breast cancer population.
METHODS: A prospective study of 370 consecutive SLNs from 115 patients was conducted at our institution. A total of 311 SLNs underwent OSNA assay analysis. All SLNs were sectioned in approximately 2-mm pieces. OSNA assay and postoperative serial sectioning were performed on alternate divided node samples. The postoperative serial sectioning histology diagnosis was used as the standard.
RESULTS: The overall rate of agreement between OSNA assay and the postoperative serial sectioning was 95.2 % [95 % confidence interval (CI) 91.6-96.9 %], with a sensitivity of 83.3 % (95 % CI 66.5-93.0 %), a specificity of 96.7 % (95 % CI 93.7-98.4 %), a positive predictive value of 76.9 % (95 % CI 60.3-88.3 %), and a negative predictive value of 97.8 % (95 % CI 95.0-99.1 %) based on the number of SLNs sampled before the discordant cases analyses. Eleven out of 15 discordant cases can be explained by tissue allocation bias.
CONCLUSIONS: Our study shows that the OSNA assay is more standardized, objective, and reproducible and can utilize more lymphoid tissue than the traditional pathological examination methods. OSNA can also distinguish between micrometastasis and macrometastasis, thereby enabling us to further study the significance of micrometastasis. Since there is a lack of standardization and reproducibility of pathological examination and diagnostic criteria of the SLNs, we recommend that the OSNA assay can be used in daily clinical diagnostic work.

Entities:  

Mesh:

Year:  2013        PMID: 23515947     DOI: 10.1007/s12282-013-0461-7

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  6 in total

1.  Intraoperative prediction of non-sentinel lymph node metastases in breast cancer using cytokeratin 19 mRNA copy number: A retrospective analysis.

Authors:  Heloïse Pina; Julia Salleron; Pauline Gilson; Marie Husson; Marie Rouyer; Agnes Leroux; Philippe Rauch; Frederic Marchal; Mathilde Käppeli; Jean-Louis Merlin; Alexandre Harlé
Journal:  Mol Clin Oncol       Date:  2022-01-10

Review 2.  One-step nucleic acid amplification (OSNA): where do we go with it?

Authors:  Yasuhiro Tamaki
Journal:  Int J Clin Oncol       Date:  2016-08-22       Impact factor: 3.402

3.  Advantages of one step nucleic acid amplification (OSNA) whole node assay in sentinel lymph node (SLN) analysis in breast cancer.

Authors:  Ana Santaballa; Helena De La Cueva; Carmen Salvador; Ana M García-Martínez; María J Guarín; David Lorente; Laura Palomar; Ismael Aznar; Fernando Dobón; Pilar Bello
Journal:  Springerplus       Date:  2013-10-17

4.  Comparison of CK-IHC assay on serial frozen sections, the OSNA assay, and in combination for intraoperative evaluation of SLN metastases in breast cancer.

Authors:  Hideo Shigematsu; Shinji Ozaki; Daisuke Yasui; Junichi Zaitsu; Daiki Taniyama; Akihisa Saitou; Kazuya Kuraoka; Hiroyasu Yamashiro; Kiyomi Taniyama
Journal:  Breast Cancer       Date:  2017-11-01       Impact factor: 4.239

5.  Evaluation of accuracy of one-step nucleic acid amplification (OSNA) in diagnosis of lymph node metastases of papillary thyroid carcinoma. Diagnostic study.

Authors:  Fabio Medas; Pierpaolo Coni; Francesco Podda; Claudia Salaris; Federico Cappellacci; Gavino Faa; Pietro Giorgio Calò
Journal:  Ann Med Surg (Lond)       Date:  2019-08-21

6.  Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review.

Authors:  Enrique Trilla; Juan Morote; Mercè Cuadras; Jacques Planas; Ana Celma; Lucas Regis; Inés M de Torres; M Eugenia Semidey
Journal:  BMC Cancer       Date:  2022-04-02       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.